Every 8-K that Creative Medical Technology Holdings, Inc. (CELZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CELZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELZ filings page.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (symbol: CELZ) is the issuer of record for a Form 8-K filing submitted to the SEC.
Creative Medical Technology Holdings, Inc. (ticker CELZ) reports that stockholders approved an amendment to its Articles of Incorporation to increase authorized common stock from 25,000,000 shares to 100,000,000 shares. A Certificate of Amendment was filed with the Nevada Secretary of State on August 28, 2026 to effect this change.
At a Special Meeting of Stockholders on August 28, 2026, holders of 3,098,886 shares, representing 65.4% of outstanding common stock as of the record date, were present in person or by proxy, constituting a quorum. Stockholders also approved the exercise in full of warrants to purchase an aggregate of 5,580,680 shares of common stock issued in a June 30, 2026 private placement.
The share increase proposal passed with 2,488,537 votes for, 595,527 against, and 14,822 abstentions. The warrant exercise proposal received 678,541 votes for, 344,460 against, 17,313 abstentions, and 1,092,794 broker non-votes.
Creative Medical Technology Holdings entered into warrant exercise inducement letters, prompting holders of warrants for 2,790,340 shares to exercise at $1.60 per share, generating approximately $4.5 million in gross proceeds. In return, the company reduced the original $2.86 exercise price and issued new Inducement Warrants for 5,580,680 shares at $1.60 per share.
The Inducement Warrants were issued in a private placement, will become exercisable only after required stockholder approval and then remain exercisable for five years. The company plans to file a resale registration statement on Form S-3 within thirty days. Roth Capital Partners will receive an 8% advisory fee on gross proceeds plus $50,000 for legal expenses. Separately, the compensation committee approved a $100,000 bonus for CEO Timothy Warbington.
Creative Medical Technology Holdings (CELZ) reported a compensation action. On November 6, 2025, the Board’s Compensation Committee approved bonuses of $100,000 for CEO Timothy Warbington and $25,000 for CFO Donald Dickerson.
The company also noted its common stock trades on Nasdaq under CELZ. An Exhibit 104 cover page interactive data file was included.
Creative Medical Technology Holdings (CELZ) entered warrant exercise inducement agreements. Holders agreed to exercise Existing Warrants for 1,116,136 shares at $3.75 per share, generating approximately $4.2 million in gross proceeds. Net proceeds will be used for working capital and general corporate purposes.
In exchange, CELZ issued Inducement Warrants to purchase 2,790,340 shares with a $3.75 exercise price, subject to reduction to the lowest VWAP during the five trading days starting on the issuance date. These Inducement Warrants are not exercisable until stockholder approval is obtained under Nasdaq rules and will then be exercisable for five years from that approval date.
The company also reduced the exercise price of certain 2022 and 2021 warrants to $4.73 per share and issued additional warrants for up to 279,036 shares to a consenting investor. Existing Warrant shares are registered under an effective Form S-3; the Inducement Warrants were issued privately, and CELZ agreed to file a Form S-3 within thirty days to register the resale of shares issuable upon their exercise. Roth Capital Partners will receive an 8% advisory fee on gross proceeds and $40,000 for legal expenses.